CCC publication: Primary analysis results of the single-arm phase II study of MOR208 plus Lenalidomide in patients with relapsed or refractory diffuse large B-Cell Lymphoma (L-MIND)

Citation: Hematological Oncology. 2019, 37, 173-74
Author:  Salles, G.; Duell, J.; González Barca, E.; Jurczak, W.; Liberati, A.M.; Nagy, Z.; Obr, A.; Gaidano, G.; Andre, M.; Kalakonda, N.; Dreyling, M.; Zinzani, P.L.; Dirnberger-Hertweck, M.; Weirather, J.; Ambarkhane, S.; Maddocks, K.